Sanofi (XSWX:SAN) Debt-to-Asset : 0.18 (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

XSWX:SAN Sanofi SA XSWX:SAN
91 GF Score
Price CHF73.20
GF Value CHF103.32
! 2 Warning Signs
View Full Analysis

What is Sanofi Debt-to-Asset?

Sanofi XSWX:SAN 91 Debt-to-Asset is 0.18 as of Jun. 2026. GuruFocus rates XSWX:SAN with a GF Score™ of 91/100 and a GF Value™ of CHF103.32. The stock has 2 warning signs investors should review.

Sanofi's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2026 was CHF6,679 Mil. Sanofi's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2026 was CHF15,031 Mil. Sanofi's Long-Term Debt & Capital Lease ObligationTotal Assets for the quarter that ended in Jun. 2026 was CHF118,845 Mil. Sanofi's debt to asset for the quarter that ended in Jun. 2026 was 0.18.

Sanofi  (XSWX:SAN) Debt-to-Asset Explanation

In the calculation of Debt-to-Asset, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Assets.

Sanofi Debt-to-Asset Related Terms

Sanofi Debt-to-Asset Historical Data

* Premium members only.

The historical data trend for Sanofi's Debt-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Sanofi Debt-to-Asset Chart

Sanofi Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Debt-to-Asset
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.19 0.17 0.15 0.14 0.16

Sanofi Semi-Annual Data
Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25 Jun26
Debt-to-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.18 0.14 0.18 0.16 0.18

XSWX:SAN vs LLY, JNJ, ABBV: Debt-to-Asset Comparison

For the Drug Manufacturers - General subindustry, Sanofi's Debt-to-Asset, along with its competitors' market caps and Debt-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Sanofi Debt-to-Asset vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Sanofi's Debt-to-Asset distribution charts can be found below:

* The bar in red indicates where Sanofi's Debt-to-Asset falls into.


XSWX:SAN
91GF Score
Sanofi SA XSWX:SAN
Debt-to-Asset is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Sanofi Debt-to-Asset Calculation

Debt to Asset measures the financial leverage a company has.

Sanofi's Debt-to-Asset for the fiscal year that ended in Dec. 2025 is calculated as

Debt-to-Asset=Total Debt / Total Assets
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Assets
=(4305.5 + 14664.266) / 118326.586
=0.16

Sanofi's Debt-to-Asset for the quarter that ended in Jun. 2026 is calculated as

Debt-to-Asset=Total Debt / Total Assets
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Assets
=(6678.943 + 15031.076) / 118845.228
=0.18

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Debt-to-Asset →
What does a Debt-to-Asset of 0.18 mean?
Sanofi (XSWX:SAN) has a Debt-to-Asset of 0.18 as of Jun. 2026. Debt-to-asset ratio represents the ratio of total debt to total assets. View historical data on Sanofi and its competitors.
Is Sanofi's Debt-to-Asset too high?
Sanofi's current Debt-to-Asset is 0.18. Overall, Sanofi has a GF Score™ of 91/100, reflecting its overall financial health beyond just this single metric.
How does Sanofi's Debt-to-Asset compare to LLY and JNJ?
Sanofi's Debt-to-Asset of 0.18 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Asset for a Drug Manufacturers company?
A good Debt-to-Asset depends on the Drug Manufacturers industry context. However, Debt-to-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Asset mean?
A high Debt-to-Asset can signal that a stock is expensive relative to its fundamentals. Debt-to-asset ratio represents the ratio of total debt to total assets. View historical data on Sanofi and its competitors. Sanofi's current Debt-to-Asset is 0.18. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sanofi stock overvalued right now?
Sanofi (XSWX:SAN) has a current Debt-to-Asset of 0.18. The stock's GF Value™ is CHF103.32, compared to a current price of CHF73.20 — trading 29.2% below its estimated fair value. The current Debt-to-Asset is 0.18. Sanofi's overall GF Score™ is 91/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Asset calculated?
Debt-to-Asset is calculated from a company's financial statements. For Sanofi (XSWX:SAN), the current Debt-to-Asset is 0.18 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Sanofi (XSWX:SAN) Overvalued in 2026?

Based on GuruFocus' analysis, Sanofi stock appears to be undervalued. The current stock price of CHF73.20 is trading 29.2% below its estimated GF Value™ of CHF103.32.

Key valuation signals for XSWX:SAN:

  • Debt-to-Asset: 0.18
  • GF Value™: CHF103.32 vs. price of CHF73.20 (29.2% below fair value)
  • GF Score™: 91/100 with 2 warning signs

No single metric tells the full story. See the XSWX:SAN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Sanofi Business Description

Address 46, Avenue de la Great Army, Paris, FRA, 75017
Sanofi develops and markets drugs with a concentration in immunology, vaccines, and rare diseases. Although the company offers a diverse array of drugs, its highest revenue generator, Dupixent, accounts for over 30% of total sales. Profits for this immunology blockbuster drug are shared with Regeneron. About 45% of total revenue comes from the United States, 20% from Europe, and 6% from China.
91GF Score

Get the complete analysis for XSWX:SAN

Debt-to-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

CHF73.20
Price
CHF103.32
GF Value